Key result
Extracorporeal cytokine adsorption shows no clear mortality benefit in sepsis or cardiac surgery.
Why the study?
The clinical benefit of extracorporeal cytokine adsorption therapy in patients undergoing cardiac surgery and in sepsis/septic shock remains uncertain due to very low-quality and inconclusive evidence.
Does extracorporeal cytokine adsorption therapy improve mortality and clinical outcomes in patients undergoing cardiac surgery or with sepsis/septic shock?
Systematic Review (n=280)
Does extracorporeal cytokine adsorption therapy improve mortality and clinical outcomes in patients undergoing cardiac surgery or with sepsis/septic shock?
Current evidence is insufficient to establish the efficacy and safety of extracorporeal cytokine adsorption therapy in cardiac surgery or sepsis, highlighting the need for well-powered trials.
Evidence inconclusive for cytokine adsorption in sepsis or cardiac surgery; leaves open need for adequately powered RCTs with patient-centered endpoints.
No takes yet. Share an insight, caveat, or question.
Goetz et al. (2021) conducted a systematic review in Sepsis/septic shock and cardiac surgery (n=280). Extracorporeal cytokine adsorption therapy vs. Standard care / concurrent control was evaluated on Mortality, length of stay in the ICU, length of hospitalization, and adverse events. Extracorporeal cytokine adsorption therapy yielded very low-quality, inconclusive evidence for mortality and adverse events in patients with sepsis or undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: